Inhibikase Therapeutics announced on January 29, 2025, its decision to cease development of its experimental Parkinson's disease drug, risvodetinib. This decision follows the drug's performance in a mid-stage study.
The company stated that the drug failed to improve patients' ability to carry out daily tasks, such as eating and walking. This outcome led to the strategic decision to discontinue the program.
The halt in development for risvodetinib marks a significant change in Inhibikase Therapeutics' pipeline focus, as it was a key neurodegenerative asset.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.